Marine Natural Product Yields Cancer Therapeutic (NCE)
- Technology Application
- While in vivo studies have not confirmed which drugs will be most useful for which cancers, studies suggest the first targets may be solid tumors, particularly colon cancer. In general, any disease or condition characterized by hyperproliferative cell growth may benefit from this therapeutic approach.
- Detailed Technology Description
- UC inventors have used human cancer bio-assays to identify, isolate and characterize novel compositions from marine cyanobacteria. Subsequent work with parent compounds and potent analogs has yielded compositions of matter, methods for synthesis and methods of using Apratoxins F & G to treat cancer.
- Supplementary Information
- Patent Number: US8598313B2
Application Number: US13581288A
Inventor: Gerwick, William H. | Tidgewell, Kevin | Valeriote, Frederick A.
Priority Date: 12 Mar 2010
Priority Number: US8598313B2
Application Date: 1 Nov 2012
Publication Date: 3 Dec 2013
IPC Current: A61K003812
US Class: 530317
Assignee Applicant: The Regents of the University of California
Title: Compositions for ameliorating cell proliferative disorders and methods of making and using them
Usefulness: Compositions for ameliorating cell proliferative disorders and methods of making and using them
Summary: For treating, preventing and/or ameliorating a disease or condition that is responsive to or ameliorated by decreasing or inhibiting cell growth, e.g. a pathological, uncontrolled or unwanted cell growth, e.g. a cancer or a metastases, or any disease or condition (e.g. allergy) or infection having a hyperproliferative cell growth component; and for ameliorating or preventing an inflammatory disease or condition that is ameliorated by decreasing or inhibiting cell growth or proliferation (claimed). The cancer is selected from lung, bone, pancreatic, skin, head or neck, cutaneous or intraocular melanoma, uterine, ovarian, rectal, cancer of the anal region, stomach, colon, breast, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, and/or pituitary adenoma.
Novelty: New apratoxin derivatives e.g. apratoxin F, apratoxin G, useful for treating/preventing/ameliorating disease/condition by decreasing/inhibiting cell growth e.g. cancer
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Cancer/Tumor
- Application No.
- 8598313
- Others
-
State Of Development
Thus far, in vivo studies with Apratoxin F have corroborated the more extensive in vivo studies with the related composition, Apratoxin A (see Luesch et al., below). Complete structures and SAR have been worked out for Apratoxins F and G. Both compositions have demonstrated solid, in vitro, toxicity against two human tumor cell lines, HCT-116 and H125. Cytotoxicity was tested in NCI H-460 human lung tumor cells and HCT-116 cells.
Intellectual Property Info
Worldwide rights available for pending patent application WO2011/112893.
Related Materials
Grindberg RV et al., Single cell genome amplification accelerates identification of the apratoxin biosynthetic pathway from a complex microbial assemblage. PLoS One. 2011 Apr 12;6(4):e18565. (link to: http://www.ncbi.nlm.nih.gov/pubmed/21533272)
Tidgewell K et al., Evolved diversification of a modular natural product pathway: apratoxins F and G, two cytotoxic cyclic depsipeptides from a Palmyra collection of Lyngbya bouillonii. Chembiochem. 2010 Jul 5;11(10):1458-66. (Link to: http://www.ncbi.nlm.nih.gov/pubmed?term=Evolved diversification of a modular natural product pathway: apratoxins F and G, two cytotoxic cyclic depsipeptides from a Palmyra collection of Lyngbya bouilloni)
Gutiérrez M et al., Apratoxin D, a potent cytotoxic cyclodepsipeptide from papua new guinea collections of the marine cyanobacteria Lyngbya majuscula and Lyngbya sordida. J Nat Prod. 2008 Jun;71(6):1099-103. (link to: http://www.ncbi.nlm.nih.gov/pubmed/21533272)
Luesch, H et al. , A functional genomics approach to the mode of action of apratoxin A. Nat Chem Biol, 2006, 2(3), 158-167 (link to: http://www.ncbi.nlm.nih.gov/pubmed?term=A Functional Genomics Approach to the Mode of Action of the Antiproliferative Natural Product Apratoxin A )Additional Technologies by these Inventors
- Anti-inflammatory compounds for dermatology and chronic inflammation
- Novel Compositions for Cancer Therapy (Proteasomes Inhibitors)
- Unique Compound Inhibits Angiogenesis in Cancer and Eye Diseases
Tech ID/UC Case
22510/2010-216-0
Related Cases
2010-216-0
- *Abstract
-
SIO scientists have mined their rare collection of marine organisms to identify, characterize and analog a proprietary, small molecule with anti-cancer properties. SAR studies have identified regions of the molecule that have yielded analogs of greatest interest. Compositions of matter and methods of use are claimed for the treatment of cancer and hyperproliferative disorders.
- *IP Issue Date
- Dec 3, 2013
- *Principal Investigator
-
Name: William Gerwick
Department:
Name: Kevin Tidgewell
Department:
Name: Fred Valeriote
Department:
- Country/Region
- USA
